A retrospective cohort study of safety and efficacy of cemiplimab in metastatic and unresectable cutaneous squamous cell carcinoma patients
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Cemiplimab (Primary)
- Indications Head and neck cancer; Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 07 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology